CN117980334A - α5β1整合素结合剂及其用途 - Google Patents

α5β1整合素结合剂及其用途 Download PDF

Info

Publication number
CN117980334A
CN117980334A CN202280049271.9A CN202280049271A CN117980334A CN 117980334 A CN117980334 A CN 117980334A CN 202280049271 A CN202280049271 A CN 202280049271A CN 117980334 A CN117980334 A CN 117980334A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antibody
integrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280049271.9A
Other languages
English (en)
Chinese (zh)
Inventor
利萨·赖纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacisia Treatment Co
Original Assignee
Pacisia Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacisia Treatment Co filed Critical Pacisia Treatment Co
Priority to CN202411049329.7A priority Critical patent/CN119161478A/zh
Publication of CN117980334A publication Critical patent/CN117980334A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280049271.9A 2021-05-11 2022-05-10 α5β1整合素结合剂及其用途 Pending CN117980334A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411049329.7A CN119161478A (zh) 2021-05-11 2022-05-10 α5β1整合素结合剂及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187371P 2021-05-11 2021-05-11
US63/187,371 2021-05-11
PCT/US2022/028520 WO2022240833A1 (en) 2021-05-11 2022-05-10 Alpha 5 beta 1 integrin binding agents and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411049329.7A Division CN119161478A (zh) 2021-05-11 2022-05-10 α5β1整合素结合剂及其用途

Publications (1)

Publication Number Publication Date
CN117980334A true CN117980334A (zh) 2024-05-03

Family

ID=84028833

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202280049271.9A Pending CN117980334A (zh) 2021-05-11 2022-05-10 α5β1整合素结合剂及其用途
CN202411049329.7A Pending CN119161478A (zh) 2021-05-11 2022-05-10 α5β1整合素结合剂及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411049329.7A Pending CN119161478A (zh) 2021-05-11 2022-05-10 α5β1整合素结合剂及其用途

Country Status (9)

Country Link
US (1) US20240279345A1 (https=)
EP (1) EP4337698A4 (https=)
JP (1) JP2024517953A (https=)
KR (1) KR20240021162A (https=)
CN (2) CN117980334A (https=)
AU (1) AU2022273290A1 (https=)
CA (1) CA3218656A1 (https=)
IL (1) IL308406A (https=)
WO (1) WO2022240833A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024102980A1 (en) * 2022-11-11 2024-05-16 Pasithea Therapeutics Corp. Anti-alpha5 integrin antibodies and uses thereof
WO2025106724A2 (en) 2023-11-15 2025-05-22 Morphic Therapeutic, Inc. USE OF ANTI-α5β1 ANTIBODIES IN THE TREATMENT OF PULMONARY HYPERTENSION AND HEART FAILURE
WO2025230866A1 (en) * 2024-04-29 2025-11-06 Pasithea Therapeutics Corp. Anti-alpha5 integrin antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
EP1625165A2 (en) * 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
HRP20150884T1 (hr) * 2006-03-21 2015-09-25 Genentech, Inc. Kombinacijska terapija koja ukljuäśuje antagoniste alfa5beta1
WO2008127655A1 (en) * 2007-04-13 2008-10-23 Biogen Idec Ma Inc. Anti-alpha 6 beta 4 integrin antibodies and uses therof
AU2008282331A1 (en) * 2007-07-27 2009-02-05 Facet Biotech Corporation Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (CD49E)
EP3612568B8 (en) * 2017-04-18 2021-12-08 Autolus Limited Cell
US11339221B2 (en) * 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use

Also Published As

Publication number Publication date
AU2022273290A9 (en) 2023-12-07
CA3218656A1 (en) 2022-11-17
CN119161478A (zh) 2024-12-20
EP4337698A1 (en) 2024-03-20
AU2022273290A1 (en) 2023-11-30
US20240279345A1 (en) 2024-08-22
KR20240021162A (ko) 2024-02-16
JP2024517953A (ja) 2024-04-23
EP4337698A4 (en) 2025-11-19
IL308406A (en) 2024-01-01
WO2022240833A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
JP7037359B2 (ja) Ｃｄ７３遮断
JP2022068161A (ja) 新規抗ｐｄ－ｌ１抗体
CN113248618B (zh) 抗pd-l1/抗lag3双特异性抗体及其用途
JP2020504627A (ja) 抗ｐｄ−１抗体及びその使用
US12146000B2 (en) Bispecific and tetravalent CD137 and FAP molecules for the treatment of cancer
AU2019274652B2 (en) Monospecific and multispecific anti-TMEFF2 antibodies and there uses
CA3128104A1 (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CN117980334A (zh) α5β1整合素结合剂及其用途
CA3231553A1 (en) Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
CN110678484A (zh) 抗pd-l1/抗lag3双特异性抗体及其用途
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
TW202337908A (zh) 抗b7-h7抗體或其抗原結合片段及製備方法與應用
CN116507639A (zh) Cd47结合剂及其用途
JP2025537255A (ja) 抗アルファ５インテグリン抗体及びその使用
HK40121590A (zh) α5β1整合素结合剂及其用途
HK40110702A (zh) α5β1整合素结合剂及其用途
TWI913270B (zh) 用於癌症治療之結合分子
WO2025230866A1 (en) Anti-alpha5 integrin antibodies and uses thereof
KR20250167591A (ko) 항-알파 v 베타 8 인테그린 항체 및 사용 방법
HK40057471B (en) Anti-pd-l1/anti-lag3 bispecific antibody and use thereof
HK40057471A (en) Anti-pd-l1/anti-lag3 bispecific antibody and use thereof
WO2024133132A1 (en) Anti-tgfbeta receptor 1 antibodies and uses thereof
BR112021003089B1 (pt) Anticorpos biespecíficos anti-pd-l1/anti-lag3 e composição farmacêutica
EA046641B1 (ru) Агенты, связывающиеся с psma, и виды их применения
HK40016537B (zh) 抗pd-1抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40110702

Country of ref document: HK